Європейський Союз - данська - EMA (European Medicines Agency)

pfizer europe ma eeig - crizotinib - carcinom, ikke-småcellet lunge - antineoplastiske midler - xalkori as monotherapy is indicated for:the first‑line treatment of adults with anaplastic lymphoma kinase (alk)‑positive advanced non‑small cell lung cancer (nsclc)the treatment of adults with previously treated anaplastic lymphoma kinase (alk)‑positive advanced non‑small cell lung cancer (nsclc)the treatment of adults with ros1‑positive advanced non‑small cell lung cancer (nsclc)the treatment of paediatric patients (age ≥6 to.

Європейський Союз - данська - EMA (European Medicines Agency)

pfizer limited - sunitinib - gastrointestinal stromal tumors; carcinoma, renal cell; neuroendocrine tumors - antineoplastiske midler - gastrointestinal stromal tumour (gist)sutent is indicated for the treatment of unresectable and/or metastatic malignant gastrointestinal stromal tumour (gist) in adults after failure of imatinib mesilate treatment due to resistance or intolerance. metastatic renal cell carcinoma (mrcc)sutent is indicated for the treatment of advanced/metastatic renal cell carcinoma (mrcc) in adults. pancreatic neuroendocrine tumours (pnet)sutent is indicated for the treatment of unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumours with disease progression in adults. experience with sutent as first-line treatment is limited (see section 5.

Європейський Союз - данська - EMA (European Medicines Agency)

pfizer limited - pneumococcal oligosaccharide serotype 18c, pneumococcal polysaccharide serotype 19f, pneumococcal polysaccharide serotype 23f, pneumococcal polysaccharide serotype 4, pneumococcal polysaccharide serotype 6b, pneumococcal polysaccharide serotype 9v, pneumococcal polysaccharide serotype 14 - pneumococcal infections; immunization - vacciner - aktiv immunisering mod sygdom forårsaget af streptococcus pneumoniae serotyper 4, 6b, 9v, 14, 18 c, 19f og 23f (herunder sepsis, meningitis, pneumoni, bakteriæmi og akut otitis media) hos spædbørn og børn fra to måneder op til fem år. brug af prevenar bør fastsættes på grundlag af de officielle anbefalinger, der tager højde for den effekt af invasiv sygdom i forskellige aldersgrupper, samt variation af serotype epidemiologi i forskellige geografiske områder.

Європейський Союз - данська - EMA (European Medicines Agency)

pfizer europe ma eeig - voriconazol - candidiasis; mycoses; aspergillosis - antimykotika til systemisk brug - voriconazol, er et bredt spektrum, triazol-svampemidler agent og er angivet i voksne og børn i alderen 2 år og derover, som følger:behandling af invasiv aspergillosis;behandling af i candidaemianon-neutropenic patienter, behandling af fluconazol-resistente alvorlige invasive candida infektioner (herunder c. krusei);behandling af alvorlige svampeinfektioner forårsaget af scedosporium spp.. og fusarium spp.. vfend bør administreres primært til patienter med progressive, eventuelt livstruende infektioner. profylakse af invasive svampeinfektioner i høj risiko allogen hæmatopoietisk stamcelletransplantation (hsct) modtagere.

Європейський Союз - данська - EMA (European Medicines Agency)

pfizer europe ma eeig - tafamidis - amyloidose - andre narkotika stoffer - vyndaqel er indiceret til behandling af transthyretinamyloidose hos voksne patienter med fase 1-symptomatisk polyneuropati for at forsinke perifer neurologisk nedsat funktion.

Європейський Союз - данська - EMA (European Medicines Agency)

pfizer europe ma eeig - tofacitinib - arthritis, reumatoid - immunosuppressiva - rheumatoid arthritistofacitinib in combination with methotrexate (mtx) is indicated for the treatment of moderate to severe active rheumatoid arthritis (ra) in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying antirheumatic drugs (dmards) (see section 5. tofacitinib can be given as monotherapy in case of intolerance to mtx or when treatment with mtx is inappropriate (see sections 4. 4 og 4. psoriatic arthritistofacitinib in combination with mtx is indicated for the treatment of active psoriatic arthritis (psa) in adult patients who have had an inadequate response or who have been intolerant to a prior disease modifying antirheumatic drug (dmard) therapy (see section 5. ulcerative colitistofacitinib is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis (uc) who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic agent (see section 5. tofacitinib is indicated for the treatment of active polyarticular juvenile idiopathic arthritis (rheumatoid factor positive [rf+] or negative [rf-] polyarthritis and extended oligoarthritis), and juvenile psoriatic arthritis (psa) in patients 2 years of age and older, who have responded inadequately to previous therapy with disease modifying antirheumatic drugs (dmards). tofacitinib can be given in combination with methotrexate (mtx) or as monotherapy in case of intolerance to mtx or where continued treatment with mtx is inappropriate. ankylosing spondylitistofacitinib is indicated for the treatment of adult patients with active ankylosing spondylitis (as) who have responded inadequately to conventional therapy.

Данія - данська - Lægemiddelstyrelsen (Danish Medicines Agency)

pfizer aps - donepezil - filmovertrukne tabletter - 10 mg

Данія - данська - Lægemiddelstyrelsen (Danish Medicines Agency)

pfizer aps - cabergolin - tabletter - 1 mg

Данія - данська - Lægemiddelstyrelsen (Danish Medicines Agency)

pfizer aps - cabergolin - tabletter - 2 mg

Данія - данська - Lægemiddelstyrelsen (Danish Medicines Agency)

pfizer aps - irinotecanhydrochloridtrihydrat - koncentrat til infusionsvæske, opløsning - 20 mg/ml